Zobrazeno 1 - 10
of 660
pro vyhledávání: '"Oncology drugs"'
Autor:
Xiangtian Ji, Xin Chen, Guozhong Lin, Kaiming Ma, Junhua Yang, Xiaofang Zhao, Suhua Chen, Jun Yang
Publikováno v:
Frontiers in Cellular Neuroscience, Vol 18 (2024)
BackgroundGliomas, originating from the most common non-neuronal cells in the brain (glial cells), are the most common brain tumors and are associated with high mortality and poor prognosis. Glioma cells exhibit a tendency to disrupt normal cell-cycl
Externí odkaz:
https://doaj.org/article/2207aeed12a048bc8b0874fc960266c0
Autor:
Rawson NSB, Stewart DJ
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 16, Pp 437-445 (2024)
Nigel SB Rawson,1– 3 David J Stewart4,5 1Macdonald-Laurier Institute, Ottawa, Ontario, Canada; 2Canadian Health Policy Institute, Toronto, Ontario, Canada; 3Centre for Health Policy Studies, Fraser Institute, Vancouver, British Columbia, Canada; 4D
Externí odkaz:
https://doaj.org/article/80efd78d319b4619997b4a4fb44bf00a
Autor:
Sandeep R. Sehdev, Nigel S. B. Rawson, Olexiy I. Aseyev, Catriona J. Buick, Marcus O. Butler, Scott Edwards, Sharlene Gill, Joanna M. Gotfrit, Cyrus C. Hsia, Rosalyn A. Juergens, Mita Manna, Joy S. McCarthy, Som D. Mukherjee, Stephanie L. Snow, Silvana Spadafora, David J. Stewart, Jason R. Wentzell, Ralph P. W. Wong, Pawel G. Zalewski
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 1803-1816 (2024)
Patient access to new oncology drugs in Canada is only possible after navigating multiple sequential systemic checkpoints for national regulatory approval, health technology assessment (HTA) and collective government price negotiation. These steps de
Externí odkaz:
https://doaj.org/article/3be7b57ba6b54e2e8cadf719163522c8
Autor:
Roohi Mohi-ud-din, Apporva Chawla, Pooja Sharma, Prince Ahad Mir, Faheem Hyder Potoo, Željko Reiner, Ivan Reiner, Dilek Arslan Ateşşahin, Javad Sharifi-Rad, Reyaz Hassan Mir, Daniela Calina
Publikováno v:
European Journal of Medical Research, Vol 28, Iss 1, Pp 1-35 (2023)
Abstract Cancer poses a significant global health challenge, with predictions of increasing prevalence in the coming years due to limited prevention, late diagnosis, and inadequate success with current therapies. In addition, the high cost of new ant
Externí odkaz:
https://doaj.org/article/9aca83a70c1942a59b7267f5ffcc5b6a
Autor:
Marya Hussain, Chelsea Wong, Eddy Taguedong, Saurav Verma, Md Mahsin, Safiya Karim, Richard Lee-Ying, Doreen A. Ezeife
Publikováno v:
Current Oncology, Vol 30, Iss 8, Pp 7706-7712 (2023)
New oncology drugs undergo detailed review prior to public funding in a single-payer healthcare system. The aim of this study was to assess how cancer drug review times impact funding recommendations. Drugs reviewed by the pan-Canadian Oncology Drug
Externí odkaz:
https://doaj.org/article/ee66eb7f138d488db02a69eff1e5be2d
Autor:
Joel Lexchin
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundThis study examined multiple aspects about the approval of new drugs: the characteristics of the drugs, the quality and quantity of information that Health Canada discloses about the demographics of patients enrolled in clinical trials, the
Externí odkaz:
https://doaj.org/article/0fed2f4a3abf4b13bee987987070042b
Autor:
Liu Liu, Zhixin Jiang, Fuming Li, Yan Wei, Jian Ming, Yi Yang, Shimeng Liu, Lizheng Shi, Yingyao Chen
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Purpose To assess the reporting quality of published economic evaluations of the negotiated oncology drugs listed for China’s 2020 National Reimbursement Drug List (NRDL). Methods A comprehensive search was conducted to identify economic e
Externí odkaz:
https://doaj.org/article/9953e0ad6b2f4692861fb228237b0602
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Analele Universităţii Constantin Brâncuşi din Târgu Jiu : Seria Economie, Iss 4, Pp 282-292 (2022)
Although the COVID-19 pandemic affected the diagnostic and treatment of cancer, it also had a positive impact on the growth of the oncology drugs market globally, with certain market segments registering an increase in demand for drugs with respect
Externí odkaz:
https://doaj.org/article/9858f7b37316449c8a4fa25835f79506
Autor:
Sasha Thomson, Louis Everest, Noah Witzke, Tina Jiao, Seanthel Delos Santos, Vivian Nguyen, Matthew C. Cheung, Kelvin K. W. Chan
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 380-391 (2022)
Abstract Background We examined if oncology drug indications with high clinical benefit, as measured by the American Society of Clinical Oncology Value Framework (ASCO‐VF) and European Society for Medical Oncology Magnitude of Clinical Benefit Scal
Externí odkaz:
https://doaj.org/article/09021889f4774c11bd1d8949aeb37c50